Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis
Objective: Animal studies suggested that angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARB) facilitate the inoculation of potentially leading to a higher risk of infection and/or disease severity. We aimed to systematically evaluate the risk of COVID-19 infection...
Main Authors: | Daniel Caldeira, Mariana Alves, Ryan Gouveia e Melo, Pedro Silvério António, Nélson Cunha, Afonso Nunes-Ferreira, Luisa Prada, João Costa, Fausto J Pinto |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | International Journal of Cardiology: Heart & Vasculature |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352906720303250 |
Similar Items
-
Angiotensin-Converting Enzyme Inhibitor / Angiotensin II Receptor Blocker in COVID-19: a Double-edged Sword or a Myth
by: Kunal Bikram Shaha, et al.
Published: (2020-05-01) -
Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
by: Athanasios Feidakis, et al.
Published: (2021-01-01) -
Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery
by: Shao-Yu Yang, et al.
Published: (2021-04-01) -
Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials
by: Nicolás Meza, et al.
Published: (2021-03-01) -
Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)